A unique medium chain triglyceride-containing micronutrient complex: Effects on migraine symptoms compared to quality of life
1 Colorado Center for Health & Sport Science, Denver, Colorado, USA COCHSS 1685 S. Colorado Blvd., Denver, CO 80222 USA.
2 University of Colorado School of Medicine, Aurora, Colorado, USA.
3 Orthopaedic Associates of Muskegon, Muskegon, Michigan, USA.
Research Article
World Journal of Advanced Research and Reviews, 2022, 13(01), 660–671
Article DOI: 10.30574/wjarr.2022.13.1.0067
Publication history:
Received on 17 December 2021; revised on 19 January 2022; accepted on 21 January 2022
Abstract:
Purpose: Migraine headaches and associated symptoms are prevalent medical issues. Medium-chain triglyceride (MCT)/nootropic-based compounds have demonstrated benefits in multiple domains. This study assessed the potential relief provided from a unique, high-concentration MCT/nootropic component blend on migraine frequency, duration, secondary symptoms, and quality of life (QOL) during a 60-day clinical investigation.
Methods: Forty (n=40) chronic migraine sufferers [migraineurs] were prospectively randomized to participate in the double-blinded study. Both intervention (n=30) and control (n=10) participants were required to maintain lifestyle patterns for the trial duration. Migraine surveys used electronic response forms to allow subjects increased ease and safety during the COVID-19 pandemic.
Results. The intervention subjects experienced reduction in migraine episodes by 53%, from 11.6 to 5.4 per month, after 60 days of supplement use. The average episode duration decreased from 260 minutes to 158 minutes, a 39% improvement. Time lost due to severe migraine effect was reduced from an average of more than five days per month to just over two per month, a decrease of 55%. A combined measure of secondary symptoms, which aggregate to illustrate migraine intensity, also decreased according to subject rating by an average of 37%. Self-assessed QOL scales improved by 43% in the intervention cohort. The control subjects showed no significant changes in any measures.
Conclusion: Consumption of a unique, nootropic brain complex significantly improved migraine symptoms, including episode frequency, duration, severity, and lost days due to dysfunction. The formulation also beneficially impacted secondary effects and self-reported QOL.
Keywords:
Migraine; Quality of Life (QOL); Headache; Ketones; Nootropics; Pain
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0